NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
Reference is made to the stock exchange announcement published by Lifecare ASA
("Lifecare" or the "Company") on 22 October 2025, regarding the proposal by
the board of directors to increase the share capital of the Company through
issuance of new shares in the Company (the "New Shares") through a partially
underwritten rights issue with preferential subscription rights for existing
shareholders (the "Subscription Rights"), raising gross proceeds of minimum
NOK 80 million and up to NOK 100 million (the "Rights Issue"). Please see the
following preliminary key information relating to the Rights Issue included
below.
Date on which the terms and conditions of the Rights Issue were announced: 22
October 2025
Last day including right: 2 January 2026
Ex-date: 5 January 2026
Record Date: 6 January 2026
Date of approval: 2 January 2026 (extraordinary general meeting)
Maximum number of New Shares: To be announced when clarified
Subscription price: To be announced when clarified
Ratio preferential rights: To be announced when clarified
Subscription ratio: To be announced when the final number of New Shares has
been determined
Managers: DNB Carnegie, a part of DNB Bank ASA, and SB1 Markets AS
Will the rights be listed: The Company will apply for trading of the
Subscription Rights on Euronext Oslo Børs
ISIN for the preferential rights: To be announced when clarified
Other information: The subscription price for the New Shares to be issued in
the Rights Issue, and thus the final number of New Shares and the exact amount
of the share capital increase will be proposed by the board of directors,
based on a recommendation from the managers, the day prior to the
extraordinary general meeting to be held on or about 2 January 2026 (the
"Rights Issue EGM"). Pursuant to the underwriting agreements for the Rights
Issue, the subscription price in the Rights Issue shall be the theoretical
share price exclusive of the Subscription Rights (TERP) based on the
volume-weighted average price (VWAP) of the Company's shares on Euronext Oslo
Børs the three trading days prior to the date of the Rights Issue EGM, less a
discount of 35%. The board of directors' resolution in this respect will be
announced through a stock exchange announcement on the day prior to the Rights
Issue EGM and be reflected in the final proposed resolution to the Rights
Issue EGM. See the stock exchange announcement published on 22 October 2025
for further information regarding the Rights Issue. The Rights Issue is
subject to approval by the Rights Issue EGM.
Contacts
For further information, please contact:
Joacim Holter, CEO, Lifecare ASA, joacim.holter@lifecare.no, +47 400 59 040
Renete Kaarvik, CFO, Lifecare ASA, renete.kaarvik@lifecare.no, +47 948 38 242
Disclosure regulation
This information is published in accordance with the requirements of the
Continuing Obligations for issuers listed on Euronext Oslo Børs.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is suitable for identifying and monitoring the occurrence of a wide
range of analytes and molecules in the human body and in pets.